As measles cases continue to climb across the United States and globally, NanoViricides, Inc. (NYSE American: NNVC) is pushing forward with its antiviral candidate NV-387, designed to treat the highly contagious disease. The clinical-stage company, which specializes in broad-spectrum antivirals built on host-mimetic nanomedicine technology, has announced plans to develop a Phase II clinical trial protocol for NV-387 as a measles treatment. The protocol will be submitted to the U.S. Food and Drug Administration (FDA) for review through the Investigational New Drug (IND) process, marking a significant step toward human trials.
The urgency of this development is underscored by the recent resurgence of measles, a disease that was declared eliminated in the U.S. in 2000 but has seen sporadic outbreaks due to declining vaccination rates. According to the Centers for Disease Control and Prevention, measles cases have been reported in multiple states this year, with outbreaks also occurring in Europe and other regions. Measles is one of the most contagious infectious diseases known, with a single infected person capable of infecting up to 90% of susceptible close contacts. Complications can be severe, including pneumonia, encephalitis, and even death, particularly in young children and immunocompromised individuals.
NanoViricides’ NV-387 has already demonstrated robust in vivo efficacy against lethal measles infection in a humanized animal model, a critical step in preclinical development. Furthermore, the FDA has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug Designation (RPDD) for NV-387 in the treatment of measles. The RPDD is particularly noteworthy as it could make the company eligible for a Priority Review Voucher upon approval of a qualifying marketing application, provided all requirements are met. This voucher, which can be sold or transferred, is a valuable incentive designed to encourage development of treatments for rare pediatric diseases.
The company’s broader pipeline includes NV-387 as a broad-spectrum antiviral with potential applications beyond measles, including respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory infections, as well as MPOX/smallpox. Additionally, NanoViricides is developing NV-HHV-1 for shingles and other candidates targeting a range of viral diseases, from herpes to Ebola. The company’s platform technology, based on TheraCour nanomedicine, aims to create “nanoviricide” agents that mimic host cells to lure and neutralize viruses.
Despite the promising preclinical data and regulatory designations, the path to a marketable measles treatment remains long and fraught with challenges. The company acknowledges that drug development is extremely lengthy and requires substantial capital, and there is no guarantee that NV-387 will prove safe and effective in human trials. The upcoming Phase II trial will be a critical milestone, providing the first real-world evidence of the drug’s potential in patients.
For investors and public health officials, the advancement of NV-387 is a development worth monitoring. If successful, it could provide a much-needed therapeutic option for measles, complementing vaccination efforts and offering a treatment for those who contract the disease. With the recent rise in cases, the importance of such an antiviral cannot be overstated.
NanoViricides is a clinical-stage company focused on creating special-purpose nanomaterials for antiviral therapy. Its lead candidate, NV-387, is being developed as a broad-spectrum antiviral, and the company plans to advance it into Phase II human clinical trials. The recent update highlights the company’s commitment to addressing measles, a disease that continues to pose a global health threat.
